^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression
Excerpt:
CH5126766 and R428 suppressed the phosphorylation of ERK and AKT, respectively, and their combination synergistically inhibited the growth of both cell lines with enhancement of apoptosis accompanied by the Bim up‐regulation.
DOI:
https://doi.org/10.1111/cas.14414
